This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ProMab
product type :
antibody
product name :
Mouse Monoclonal Antibody to SOD1
catalog :
20349
quantity :
100μl
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
6F5
The same clone is also sold as:
The same clone is also sold as:
- Boster: M00238-2
- MyBioSource: MBS850323
- Abnova: MAB10394
- Invitrogen: MA5-15520
- OriGene: AM06340SU-N
reactivity :
human, mouse
application :
western blot, ELISA, immunocytochemistry, flow cytometry
product information
Catalog :
20349
Title :
Mouse Monoclonal Antibody to SOD1
Species :
Human; Mouse
Clone :
6F5;
lsotype :
Mouse IgG1
Size :
100μl
Storage :
4℃; -20℃ for long term storage
Description :
SOD1 (superoxide dismutase 1, soluble), also known as ALS. The protein binds copper and zinc ions and is one of two isozymes responsible for destroying free superoxide radicals in the body. The encoded isozyme is a soluble cytoplasmic protein, acting as a homodimer to convert naturally-occuring but harmful superoxide radicals to molecular oxygen and hydrogen peroxide. The other isozyme is a mitochondrial protein. Mutations in this gene have been implicated as causes of familial amyotrophic lateral sclerosis (ALS), a progressive degenerative disease of motor neurons. Rare transcript variants have been reported for this gene.
Immunogen :
Purified recombinant fragment of human SOD1 expressed in E. Coli.
Formulation :
Ascitic fluid containing 0.03% sodium azide.
Applications :
ELISA: 1/10000; WB: 1/500 - 1/2000; ICC: 1/200 - 1/1000; FCM: 1/200 - 1/400
References :
1. Apoptosis. 2005 May;10(3):499-502. ; 2. Hum Mol Genet. 2008 Nov 1;17(21):3303-17.
Type :
Monoclonal Antibody
MW :
18kDa
Aliases :
ALS; SOD; ALS1; IPOA; homodimer
company information
ProMab
5221 Central Avenue, Suite 200
Richmond, CA 94804
Richmond, CA 94804
info@promab.com
http://www.promab.com1-866-339-0871
headquarters: USA
questions and comments